Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 21Gastrointestinal 10Thoracic 5Breast 5Sarcoma 4Tumor-Agnostic 3Other solid neoplasm 3Other hematologic neoplasm 3Head & Neck 3Gynecologic 3Dermatologic 3CNS 3Plasma cell 2NET 1Myeloid 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Melanoma 3Carcinoma, Medullary 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1HIV Infections 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × cabozantinib × Dermatologic × Clear all
NCT04514484 2026-05-28

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

Phase 1 Active not recruiting
8 enrolled 32 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01709435 2023-12-22

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled 20 charts
CNSDermatologicHead & Neck

Melanoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT01835184 2014-09-25

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
5 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡